Heart, Lung and Circulation
Volume 16, Issue 1 , Pages 7-9 , February 2007

Benefits of Drug-Eluting Stents in Coronary Heart Disease Treatment with Emphasis on the Diabetic Subgroup

Received 26 January 2006

References 

  1. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  2. Morice MC, Serruys PW, Sousa JE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  3. Holmes DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–640
  4. Grube E, Silber S, Hauptmann KE. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  5. Stone GW, Ellis SG, Cox DA. TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947
  6. Colombo A, Drzewiecki J, Banning A TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  7. Moses JW, O'Shaughnessy C, Caputo R. The US multicenter, randomized, double blind study of the sirolimus-eluting stent in coronary lesions: safety outcomes at 9 months. Eur Heart J. 2002;264
  8. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  9. Jenkins NP, Prendergast BD, Thomas M. Drug eluting coronary stents. BMJ. 2002;325:1315–1316
  10. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet. 2003;361:247–249
  11. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377–381
  12. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  13. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519–1521
  14. Grundy SM, D’Agostino RB, Mosca L. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation. 2001;104:491–496
  15. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation. 2003;108:1655–1661
  16. Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med. 2003;139:824–834
  17. Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol. 1998;32(Suppl. 3):S54–S61
  18. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, et al. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res. 1997;86:173–180
  19. Huvers FC, De Leeuw PW, Houben AJ, De Haan CH, Hamulyak K, Schouten H, et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes. 1999;48:1300–1307
  20. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511–2515
  21. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, et al. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res. 1997;86:173–180
  22. Peppa M, Uribarri J, Vlassara H, et al. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes. 2003;21:186–187
  23. Jakus A, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res. 2004;53:131–142
  24. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol. 2005;25(5):879–882
  25. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273–278
  26. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993;50:125–134
  27. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol. 1992;41:32–39
  28. Gray RP, Panahloo A, Mohamed-Ali V, Patterson DL, Yudkin JS. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis. 1997;130:171–178
  29. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators . A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498–1505
  30. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and Non-Q-Wave myocardial infarction. N Engl J Med. 1998;338:1488–1497
  31. The PARAGON investigators. International randomised, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 1998;97:2386–95.
  32. The PURSUIT trial investigators . Inhibition of plateletglycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New Engl J Med. 1998;339:436–443
  33. The GUSTO IV-ACS Investigators . Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet. 2001;357:1915–1924
  34. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  35. Steinhubl SR, Berger PB, Mann JT. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420
  36. Pérez A, Caixàs A, Carreras G. Lipoprotein compositional abnormalities in type I diabetes: effect of improved glycaemic control. Diabetes Res Clin Pract. 1997;36:83–90
  37. Cominacini L, Garbin U, Pastorino AM. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res. 1994;26:173–184
  38. Dibra A, Kastrati A, Mehilli J. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663–670

PII: S1443-9506(06)00223-X

doi: 10.1016/j.hlc.2006.09.005

Heart, Lung and Circulation
Volume 16, Issue 1 , Pages 7-9 , February 2007

Article Tools